For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.
This MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists.
To evaluate the proportion of patients with objective response to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma.
DiagnosisPatients had a sample of tumor tested by a MATCH-designated lab. The test showed the tumor has a gene change, or mutation targeted by one or more of the drugs used in this study.
Patient has cancer that has become worse following treatment, or no standard therapy exists for that type of cancer.
Patient must have actionable mutation of interest determined by molecular profiling.
Patients must sign an approved informed consent and authorization permitting release of personal health information.
Tissue is sent for molecular testing and if an actionable mutation is identified patients are placed in various substudies. Treatment in substudies is based on specific mutation present.
For more information, visit ClinicalTrials.gov